Home Newsfeeds SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $64

SVB Leerink Maintains Outperform on Rocket Pharmaceuticals, Lowers Price Target to $64

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $66 to $64.

byBenzinga Newsdesk

July 6, 2022

1 minute read

SVB Leerink analyst Mani Foroohar maintains Rocket Pharmaceuticals (NASDAQ:RCKT) with a Outperform and lowers the price target from $66 to $64.

Truist Securities Maintains Hold on Gilead Sciences, Raises Price Target to $76

By Benzinga Newsdesk

September 15, 7:43 AM

Truist Securities analyst Robyn Karnauskas maintains Gilead Sciences (NASDAQ:GILD) with a Hold and raises the price target from $71 to $76.

GILD

Altria Clocks 3.5% Revenue Decline In Q3; Narrows FY22 EPS Forecast

By Shivani Kumaresan

October 27, 1:51 PM

Altria Group Inc (NYSE:MO) reported a third-quarter FY22 sales decline of 3.5% year-on-year to $6.55 billion. Revenue for smokeable products decreased…

Hasbro To Rally Over 42%? Here Are 10 Other Analyst Forecasts For Tuesday

By Lisa Levin

August 22, 8:12 AM

UBS lowered the price target for The Estée Lauder Companies Inc. (NYSE: EL) from $207 to $172. UBS analyst Peter Grom maintained a Neutral rating. Estée Lauder shares gained 0.1% to $151.10 in pre-market trading.

ACN